Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors

International Review of Neurobiology

Volumn 95, Issue C, 2010, Pages 73-118

  Nissinen, Erkki ^a   Männistö, Pekka T ^b  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Bifunctional; Bisubstrate; COMT; COMT inhibition; COMT overexpression; COMT variant; Entacapone; Enzyme kinetics; Levodopa; Nebicapone; Nitecapone; Nitrocatechol; Structure; Tolcapone; Transgenic

Indexed keywords

2,5 DICHLORO 3 [5 (3,4 DIHYDROXY 5 NITROPHENYL) 1,2,4 OXADIAZOL 3 YL] 4,6 DIMETHYLPYRIDINE 1 OXIDE; 6 NITRONORADRENALINE; ANTIPARKINSON AGENT; BENSERAZIDE; BIA 3 335; BIA 8 176; BIA 9 1067; CARBIDOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; METHYLTRANSFERASE INHIBITOR; N (6 OXO 1H PYRID 2 YL) N',N' DIPROPYLFORMAMIDINE; NEBICAPONE; NITECAPONE; NOMIFENSINE; NORADRENALIN; PARGYLINE; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG;

AMNESIA; AREA UNDER THE CURVE; BOOK; CATALEPSY; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM INJURY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; GENE DISRUPTION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARKINSON DISEASE; PHYSICAL CHEMISTRY; POTENTIOMETRY; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE;

EID: 78649345237     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381326-8.00005-3     Document Type: Chapter

References (176)

1. Abdolmaleky H.M., Cheng K.H., Faraone S.V., Wilcox M., Glatt S.J., Gao F., Smith C.L., Shafa R., Aeali B., Carnevale J., Pan H., Papageorgis P., Ponte J.F., Sivaraman V., Tsuang M.T., Thiagalingam S. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 2006, 15:3132-3145.
2. Acquas E., Carboni E., de Ree R.H.A., Da Prada M., Di Chiara G. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J. Neurochem. 1992, 59:326-330.
3. Anderson G.L., Bussolotti D.L., Coward J.K. Synthesis and evaluation of some stable multisubstrate adducts as inhibitors of catechol-O-methyltransferase. J. Med. Chem. 1981, 24:1271-1277.
4. Axelrod J., Senoh S., Witkop B. O-Methylation of catechol amines in vivo. J. Biol. Chem. 1958, 233:697-701.
5. Axelrod J., Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 1958, 233:702-705.
6. Babovic D., O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Tighe O., Croke D.T., Karayiorgou M., Gogos J.A., Cotter D., Waddington J.L. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 2008, 155:1021-1029.
7. Babovic D., O'Tuathaigh C.M., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., Karayiorgou M., Gogos J.A., Cotter D., Waddington J.L. Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav. Brain Res. 2007, 183:236-239.
8. Bäckström R., Honkanen E., Pippuri A., Kairisalo P., Pystynen J., Heinola K., Nissinen E., Lindén I.-B., Männist P.T., Kaakkola S., Pohto P. Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J. Med. Chem. 1989, 32:841-846.
9. Bai H.W., Shim J.Y., Yu J., Zhu B.T. Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases. Chem. Res. Toxicol. 2007, 20:1409-1425.
10. Bai H.W., Wang P., Zhu B.T. Characterization of a novel human catechol-O-methyl-transferase mutant with triplet point mutations. Int. J. Mol. Med. 2008, 22:769-779.
11. Bailey K., Tan E.W. Synthesis and evaluation of bifunctional nitrocatechol inhibitors of pig liver catechol-O-methyltransferase. Bioorg. Med. Chem. 2005, 13:5740-5749.
12. Ball P., Knuppen R., Haupt M., Breuer H. Interactions between estrogens and catechol amines. III. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the catechol-O-methyltransferase. J. Clin. Endocrinol. Metab. 1972, 34:736-746.
13. Banger M., Hiemke C., Haupt M., Knuppen R. Excretion of 2- and 3-monomethyl ethers of 2-hydroxyestrogens in healthy male volunteers. Eur. J. Endocrinol. 1996, 13:193-197.
14. Bertocci B., Miggiano V., Da Prada M., Dembic Z., Lahm H.W., Malherbe P. Human catechol-O-methyltransferase: Cloning and expression of the membrane-associated form. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:1416-1420.
15. Bonifácio M.J., Archer M., Rodrigues M.L., Matias P.M., Learmonth D.A., Carrondo M.A., Soares-Da-Silva P. Kinetics and crystal structure of catechol-O-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Mol. Pharmacol. 2002, 62:795-805.
16. Bonifácio M.J., Palma P.N., Almeida L., Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug. Rev. 2007, 13:352-379.
17. Bonifácio M.J., Vieira-Coelho M.A., Soares-da-Silva P. Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. Eur. J. Pharmacol. 2003, 460:163-170.
18. Bonifati V., Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol. Ther. 1999, 81:1-36.
19. Borges N., Vieira-Coelho M.A., Parada A., Soares-da-Silva P. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J. Pharmacol. Exp. Ther. 1997, 282:812-817.
20. Borgulya J., Bruderer H., Bernauer K., Zürcher G., Da Prada M. Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: Synthesis and structure-activity studies. Helv. Chim. Acta. 1989, 72:952-968.
21. Borgulya J., Da Prada M., Dingemanse J., Scherschlicht R., Schläppl B., Zürcher G. Ro 40-7592 (3,4-dihydroxy-4'-methyl-5-nitrobenzophenone), catecholamine-O-methyltransferase (COMT) inhibitor. Drugs Future 1991, 16:719-721.
22. Boudikova B., Szumlanski C., Maidak B., Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 1990, 48:381-389.
23. Brannan T., Martinez-Tica J., Yahr M.D. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats. Neurology 1992, 42:683-685.
24. Brannan T., Prikhojan A., Yahr M.D. Peripheral and central inhibitors of catechol-O-methyl transferase: Effects on liver and brain COMT activity and L-DOPA metabolism. J. Neural. Transm. Gen. Sect. 1997, 104:77-87.
25. Brevitt S.E., Tan E.W. Synthesis and in vitro evaluation of two progressive series of bifunctional polyhdroxybenzamide catechol-O-methyltransferase inhibitors. J. Med. Chem. 1997, 40:2035-2039.
26. Budygin E.A., Gainetdinov R.R., Kilpatrick M.R., Rayevsky K.S., Männist P.T., Wightman R.M. Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur. J. Pharmacol. 1999, 370:125-131.
27. Cheng M.C., Liao D.L., Hsiung C.A., Chen C.Y., Liao Y.C., Chen C.H. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int. J Neuropsychopharmacol. 2008, 11:207-216.
28. Cohn C.K., Axelrod J. The effect of estradiol on catechol-O-methyltransferase activity in rat liver. Life Sci. 1971, 10:1351-1354.
29. Cumming P., Brown E., Damsma G., Fibiger H. Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: An in vivo microdialysis study. J. Neurochem. 1992, 59:1905-1914.
30. Da Prada M., Zürcher G., Kettler R., Colzi A. New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. Basal Ganglia III 1991, 723-732. Plenum Press, New York. G. Bernardi, M. Carpenter, G. Di Chiara, P. Stanzione (Eds.).
31. DeSanti C., Donatelli P., Giulianotti P.C., Pietrabissa A., Mosca F., Pacifici G.M. Interindividual variability of histamine N-methyltransferase in the human liver and kidney. Xenobiotica. 1998, 28:571-577.
32. Di Giovanni S., Eleuteri E., Paleologou K.E., Yin G., Zweckstetter M., Carrupt P.-A., Lashuel H.A. Entacapone and tolcapone, two catechol-O-methyltransferase inhibitors (ICOMT), block fibril formation of α-synuclein and Β-amyloid and protect against amyloid induced toxicity. J. Biol. Chem. 2010, In press.
33. Dingemanse J. Catechol-O-methyltransferase inhibitors: clinical potential in the treatment of Parkinson's disease. Drug Devel. Res. 1997, 42:1-25.
34. Dingemanse J., Jorga K.M., Schmitt M., Gieschke R., Fotteler B., Zürcher G., Da Prada M., van Brummelen P. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 1995, 57:508-517.
35. Ekblom J., Aquilonius S.-M., Jossan S.S. Differential increases in catecholamine metabolizing enzymes in amyotrophic lateral sclerosis. Exp. Neurol. 1993, 123:289-294.
36. Ekblom J., Garpenstrand H., Tottmar O., Prince J., Oreland L. A cell culture model of cerebral ischemia as a convenient system to screen for neuroprotective drugs. J. Neural. Transm. 1998, 52(Suppl.):93-98.
37. Ericsson A.D. Potentiation of the L-dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J. Neurol. Sci. 1971, 14:193-197.
38. Etemadzadeh E., Koskinen L., Kaakkola S. Computerized rotometer apparatus for recording circling behavior. Methods Find. Exp. Clin. Pharmacol. 1989, 11:399-407.
39. Flemström G., Säfsten B. Role of dopamine and other stimuli of mucosal bicarbonate secretion in duodenal protection. Dig. Dis. Sci. 1994, 39:1839-1842.
40. Flemström G., Säfsten B., Jedstedt G. Stimulation of mucosal alkaline secretion in rat duodenum by dopamine and dopaminergic compounds. Gastroenterology 1993, 104:825-833.
41. Forsberg M., Huotari M., Savolainen J., Männist P.T. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. Eur. J. Pharm. Sci. 2005, 24:503-511.
42. Forsberg M., Juvonen R., Helisalmi P., Leppänen J., Gogos J., Karayiorgou M., Männist P.T. Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370:279-289.
43. Forsberg M., Lehtonen M., Heikkinen M., Savolainen J., Järvinen T., Männist P.T. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: A comparative study in rats. J. Pharmacol. Exp. Ther. 2003, 304:498-506.
44. Fredriksson A., Archer T. Synergistic interactions between COMT-/MAO-inhibitors and L-dopa in MPTP-treated mice. J. Neural. Transm. Gen. Sect. 1995, 102:19-32.
45. Funaki T., Onodera H., Ushiyama N., Tsukamoto Y., Tagami C., Fukazawa H., Kuruma I. The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats. J. Pharm. Pharmacol. 1994, 46:571-574.
46. Funaki T., Onodera H., Ushiyama N., Tsukamoto Y., Tagami C., Fukazawa H., Kuruma I. Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats. J. Pharm. Pharmacol. 1995, 47:539-542.
47. Garris P.A., Wightman R.M. Distinct pharmacological regulation of evoked dopamine efflux in the amygdala and striatum of the rat in vivo. Synapse 1995, 20:269-279.
48. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Nat. Acad. Sci. U.S.A. 1998, 95:9991-9996.
49. Goodman J.E., Jensen L.T., Ping H., Yager J.D. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogentics. 2002, 12:517-528.
50. Guldberg H.C., Marsden C.A. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol. Rev. 1975, 27:135-206.
51. Haasio K., Huotari M., Nissinen E., Männist P.T. Tissue histopathology, clinical chemistry and behaviour of adult COMT-gene disrupted mice. J. Appl. Toxicol. 2003, 23:213-219.
52. Haramaki N., Stewart D.B., Aggarwal S., Kawabata T., Packer L. Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Biochem. Pharmacol. 1995, 50:839-843.
53. Heeringa M.J., d'Agostini F., DeBoer P., Da Prada M., Damsma G. Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior. J. Neural. Transm. Gen. Sect. 1997, 104:593-603.
54. Helkamaa T., Männist P.T., Rauhala P., Cheng Z.J., Finckenberg P., Huotari M., Gogos J., Karayiorgou M., Mervaala E.M.A. Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. J. Hypert. 2003, 21:2365-2374.
55. Himori N., Mishima K. The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice. Experientia. 1994, 50:939-942.
56. Hiroaki, S., Takehiro, I., Satoko, K., Hitoshi, I., Masako, Y., Yasunori, U., and Nobuyuki, T. (2009). Novel catechol derivative, pharmaceutical composition containing the same and use of those. WIPO Patent Appl. WO/2009/081,892 A1.
57. Huotari M., García-Horsman J.A., Karayiorgou M., Gogos J.A., Männist P.T. D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl.) 2004, 172:1-10.
58. Huotari M., Gogos J.A., Karayiorgou M., Koponen I., Forsberg M., Raasmaja A., Hyttinen J., Männist P.T. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur. J. Neurosci. 2002, 15:246-256.
59. Huotari M., Santha M., Lucas L.R., Karayiorgou M., Gogos J.A., Männist P.T. Effect of Dopamine Uptake Inhibition on Brain Catecholamine Levels and Locomotion in Catechol-O-methyltransferase-Disrupted Mice. J. Pharmacol. Exp. Ther. 2002, 303:1309-1316.
60. Jeffery D., Roth J.A. Kinetic reaction mechanism for magnesium binding to membrane-bound and soluble catechol-O-methyltransferase. Biochemistry 1987, 26:2955-2958.
61. Jiang H., Xie T., Ramsden D.B., Ho S.L. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 2003, 45:1011-1018.
62. Kaakkola S., Gordin A., Järvinen M., Wikberg T., Schultz E., Nissinen E., Pentikäinen P.J., Rita H. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin. Neuropharmacology 1990, 13:436-447.
63. Kaakkola S., Gordin A., Männist P.T. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase (COMT). Gen. Pharmacol. 1994, 25:813-824.
64. Kaakkola S., Wurtman R.J. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res. 1992, 587:241-249.
65. Kaakkola S., Wurtman R.J. Effects of COMT inhibitors and L-dopa with and without carbidopa on extracellular dopamine in the rat striatum. J. Neurochem. 1993, 60:137-144.
66. Käenmäki M., Tammimäki A., Garcia-Horsman A., Myöhänen T., Schendzielorz N., Karayiorgou M., Gogos J., Männist P.T. Importance of membrane-bound catechol-O-methyltransferase in L-dopa metabolism, a pharmacokinetic study in two types of Comt gene modified mice. Brit. J. Pharmacol. 2009, 158:1884-1894.
67. Käenmäki M., Tammimäki A., Pakarinen K., Kambur O., Karvonen L., Karayiorgou M., Gogos J., Männist P.T. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J. Neurochem 2010, 114:1745-1755.
68. Katajamäki J., Honkanen A., Piepponen T.P., Linden I.-B., Zharkovsky A., Ahtee L. Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats. Pharmacol. Biochem. Behav. 1998, 60:23-26.
69. Kelland M.D., Freeman A.S., Rubin J., Chiodo L.A. Ascending afferent regulation of rat midbrain dopamine neurons. Brain Res. Bull. 1993, 31:539-546.
70. Keränen T., Gordin A., Karlsson M., Korpela K., Pentikäinen P.J., Rita H., Schultz E., Seppäl L., Wikberg T. Inhibition of soluble catechol-O-methyltransferase and single dose pharmacokinetics after oral and intravenous administration of entacapone. Eur. J. Clin. Pharmacol. 1994, 46:1551-1557.
71. Kern C., Bernards C.M. Ascorbic acid inhibits spinal meningeal catechol-O-methyltransferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology 1997, 86:405-409.
72. Khromova I., Rauhala P., Zolotov N., Männistä P.T. Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the nucleus basalis of Meynert. Neuroreport 1995, 6:1219-1222.
73. Khromova I., Voronina T., Kraineva V.A., Zolotov N., Männist P.T. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behav. Brain Res. 1997, 86:49-57.
74. Kiss L.E., Ferreira H.S., Torrão L., Bonifácio M.J., Palma P.N., Soares-da-Silva P., Learmonth D.A. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J. Med. Chem. 2010, 53:3396-3411.
75. Knutson L., Knutson T.W., Flemström G. Endogenous dopamine and duodenal bicarbonate secretion in humans. Gastroenterology 1993, 104:1409-1413.
76. Larsen K.R., Dajani E.Z., Dajani N.E., Dayton M.T., Moore J.G. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs. Dig. Dis. Sci. 1998, 43:1806-1813.
77. Lautala P., Ulmanen I., Taskinen J. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol. Pharmacol. 2001, 59:393-402.
78. Learmonth D.A., Bonifácio M.J., Soares-da-Silva P. Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J. Med. Chem. 2005, 48:8070-8078.
79. Learmonth D.A., Palma P.N., Vieira-Coelho M.A., Soares-da-Silva P. Synthesis, biological evaluation, and molecular modeling Studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J. Med. Chem. 2004, 47:6207-6217.
80. Learmonth D.A., Vieira-Coelho M.A., Benes J., Alves P.C., Borges N., Freitas A.P., Soares-da-Silva P. Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. J. Med. Chem. 2002, 45:685-695.
81. Lerner C., Masjost B., Ruf A., Gramlich V., Jakob-Roetne R., Zürcher G., Borroni E., Diederich F. Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity. Org. Biomol. Chem. 2003, 1:42-49.
82. Lerner C., Ruf A., Gramlich V., Masjost B., Zürcher G., Jakob-Roetne R., Borroni E., Diederich F. X-ray crystal structure of a bisubstrate inhibitor bound to enzyme catechol-O-methyltransferase: A dramatic effect of inhibitor preorganization on binding affinity. Angew. Chem. Int. Ed. 2001, 40:4040-4042.
83. Levin E.D., Mcgurk S.R., Rose J.E., Butcher L.L. Cholinergic-dopaminergic interactions in cognitive performance. Behav. Neural Biol. 1990, 54:271-299.
84. Li Y.S., Wirth T., Huotari M., Laitinen K., MacDonald E., Männist P.T. No change of brain extracellular catecholamine levels after acute COMT inhibition: a microdialysis study in anaesthetized rats. Eur. J. Pharmacol. 1998, 356:127-137.
85. Liljequist R., Haapalinna A., Åhlander M., Li Y.-H., Männist P.T. Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav. Brain Res. 1997, 82:195-202.
86. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210.
87. Lundström K., Tenhunen J., Tilgmann C., Karhunen T., Panula P., Ulmanen I. Cloning, expression and structure of catechol-O-methyltransferase. BBA-Prot. Struct. Mol. Enzymol. 1995, 1251:1-10.
88. Maj J., Rogóz Z., Skuza G., Sowinska H., Superata J. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinsons disease. J. Neural. Transm. Park. Dis. Dement. Sect. 1990, 2:101-112.
89. Malherbe P., Bertocci B., Caspers P., Zürcher G., Da Prada M. Expression of functional membrane-bound and soluble catechol-O-methyltransferase in Escherichia coli and a mammalian cell line. J. Neurochem. 1992, 58:1782-1789.
90. Männist P.T. Catechol-O-methyltransferase: Characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors. Advances in Pharmacology. Catecholamines: Bridging Basic Science with Clinical Medicine 1998, 324-328. Academic Press, San Diego, CA. D. Goldstein, G. Eisenhofer, R. McCarty (Eds.).
91. Männist P.T., Kaakkola S. New selective COMT inhibitors: useful adjuncts for Parkinson's disease?. Trends Pharmacol. Sci. 1989, 10:54-56.
92. Männist P.T., Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. 1990, 66:317-323.
93. Männistö P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51:593-628.
94. Männist P.T., Kaakkola S., Nissinen E., Lindén I.-B., Pohto P. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci. 1988, 43:1465-1471.
95. Männist P.T., Lang A., Rauhala P., Soosaar A., Vasar E. Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. Eur. J. Pharmacol. 1995, 274:229-233.
96. Männist P.T., Tuomainen P., Tuominen R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 1992, 105:569-574.
97. Männist P.T., Ulmanen I., Lundström K., Taskinen J., Tenhunen J., Tilgmann C., Kaakkola S. Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. 1992, 39:291-350.
98. Männist P.T., Ulmanen I., Taskinen J., Kaakkola S. Catechol O-methyltransferase (COMT) and COMT inhibitors. Design of Enzyme Inhibitors as Drugs 1994, 625-647. Oxford University Press, Oxford. M. Sandler, H.J. Smith (Eds.).
99. Marcocci L., Maguire J.J., Packer L. Nitecapone: a nitric oxide radical scavenger. Biochem. Mol. Biol. Intern. 1994, 34:531-541.
100. Masjost B., Ballmer P., Borroni E., Zürcher G., Winkler F.K., Jakob-Roetne R., Diederich F. Structure-based design, synthesis and in vitro evaluation of bisubstrate inhibitors for catechol-O-methyltransferase (COMT). Chem. Eur. J. 2000, 6:971-982.
101. McGeer E.G., Kremer B., Hayden M.R. Monoamines and their metabolites in Huntington's disease brain: Evidence for decreased catechol-O-methyltransferase activity. Biol. Psychiatry. 1993, 33:551-553.
102. Moreau J.L., Borgulya J., Jenck F., Martin J.R. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav. Pharmacol. 1994, 5:344-350.
103. Napolitano A., Bellini G., Borroni E., Zürcher G., Bonuccelli U. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Parkinsonism Relat. Disord. 2003, 9:145-150.
104. Napolitano A., Cesura A.M., Da Prada M. The role of monoamine oxidase and catechol-O-methyltransferase in dopaminergic neurotransmission. J. Neural. Transm. Suppl. 1995, 45:35-45.
105. Napolitano A., Zürcher G., Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats. Eur. J. Pharmacol. 1995, 273:215-221.
106. Nissinen E., Kaheinen P., Pentilla K.E., Kaivola K., Linden I.B. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur. J. Pharmacol. 1997, 340:287-294.
107. Nissinen E., Lindén I.-B., Pohto P. Antioxidant properties of nitecapone are potentiated by glutathione. Biochem. Mol. Biol. Intern. 1995, 35:387-395.
108. Nissinen E., Lindén I.-B., Schultz E., Kaakkola S., Männist P.T., Pohto P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur. J. Pharmacol. 1988, 153:263-269.
109. Nissinen E., Lindén I.-B., Schultz E., Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch. Pharmacol. 1992, 346:262-266.
110. Nissinen E., Tuominen R.K., Perhoniemi V., Kaakkola S. Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci. 1988, 42:2609-2614.
111. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 1984, 7:35-79.
112. Odlind C., Reenil I., Männist P.T., Juvonen R., Uhlén S., Gogos J., Karayiorgou M., Hansell P. Reduced natriuretic response to sodium loading in COMT gene deleted mice. BMC Physiol. 2002, 2:14.
113. Orama M., Tilus P., Taskinen J., Lotta T. Iron(III)-chelating properties of the novel catechol-O-methyltransferase inhibitor entacapone in aqueous solution. J. Pharm. Sci. 1997, 86:827-831.
114. Palma P.N., Bonifácio M.J., Loureiro A.I., Wright L.C., Learmonth D.A., Soares-da-Silva P. Drug Metab. Disposition 2003, 31:250-258.
115. Palma P.N., Rodrigues M.L., Archer M., Bonifácio M.J., Loureiro A.I., Learmonth D.A., Carrondo M.A., Soares-da-Silva P. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation. Mol. Pharmacol. 2006, 70:143-153.
116. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., Chen J. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J. Neurosci. 2008, 28:8709-8723.
117. Parada A., Loureiro A.I., Vieira-Coelho M.A., Hainzl D., Soares-da-Silva P. BIA-3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-dopa to the brain and reduces its O-methylation. Eur. J. Pharmacol. 2001, 420:27-32.
118. Parada A., Soares-da-Silva P. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain. Pharmacology 2003, 68:29-37.
119. Parvez S., Parvez S.H., Youdim M.B.H. Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy. Br. J. Pharmacol. 1975, 53:241-246.
120. Paulini R., Lerner C., Jakob-Roetne R., Zürcher G., Borroni E., Diederich F. Bisubstrate inhibitors of the enzyme catechol-O-methyltransferase (COMT): efficient inhibition despite the lack of a nitro group. Chem. Biochem. 2004, 5:1270-1274.
121. Pentikäinen M.O., Lindstedt K.A., Kovanen P.T. Inhibition of oxidative modification of LDL by nitecapone. Arterioscler. Thromb. Vasc. Biol. 1995, 15:740-747.
122. Pérez R.A., Fernández-Alvarez E., Nieto O., Piedrafita F.J. Dihydroxy-nitrobenzaldehydes and hydroxymethoxynitrobenzaldehydes: synthesis and biological activity as catechol-O-methyltransferase inhibitors. J. Med. Chem. 1992, 35:4584-4588.
123. Pérez R.A., Fernández-Alvarez E., Nieto O., Piedrafita F.J. Inhibition of catechol-O-methyltransferase by 1-vinyl derivatives of nitrocatechols and nitroguaiacols. Kinetics of the irreversible inhibition by 3-(3-hydroxy-4-methoxy-5-nitro benzylidene)-2,4-pentanedione. Biochem. Pharmacol. 1993, 45:1973-1981.
124. Pérez R.A., Fernández-Alvarez E., Nieto O., Piedrafita F.J. Kinetics of the reversible tight-binding inhibition of pig liver catechol-O-methyltransferase by [2-(3,4-dihydroxy-2-nitrophenyl)vinyl]phenyl ketone. J. Enzyme Inhib. 1994, 8:123-131.
125. Pertovaara A., Wei H., Kalmari J., Ruotsalainen M. Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp. Neurol. 2001, 167:425-434.
126. Rautio J., Leppänen J., Lehtonen M., Laine K., Koskinen M., Pystynen J., Savolainen J., Sairanen M. Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor. Bioorg. Med. Chem. Lett. 2010, 20:2614-2616.
127. Reches A., Fahn S. Catechol-O-methyltransferase and Parkinson's disease. Adv. Neurol. 1984, 40:171-179.
128. Reenil I., Tuomainen P., Tilgmann C., Männist P.T. Opposite effects of ethanol on recombinant membrane-bound and soluble activities of catechol-O-methyltransferase. Pharmacol. Toxicol. 1995, 77:414-416.
129. Reilly D.K., Hershey L., Rivera-Calimlim L., Shoulson I. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. Adv. Neurol. 1983, 37:51-60.
130. Rivas E., de Ceballos M.L., Nieto O., Fontenla J.A. In vivo effects of new inhibitors of catechol-O-methyltransferase. Br. J. Pharmacol. 1999, 126:1667-1673.
131. Rivett A.J., Eddy B., Roth J.A. Contribution of sulfate conjugation, deamination and O-methylation of dopamine and norepinephrine in human brain. J. Neurochem. 1982, 39:1009-1016.
132. Rivett A.J., Roth J.A. Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol-O-methyltransferase. Biochemistry 1982, 21:1740-1742.
133. R (tolcapone), Product Monograph 1997, F. Hoffman-La Roche, Basel, Switzerland.
134. Roth J.A. Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev. Physiol. Biochem. Pharmacol. 1992, 120:1-29.
135. Salminen M., Lundström K., Tilgmann C., Savolainen R., Kalkkinen N., Ulmanen I. Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene 1990, 93:241-247.
136. Sasaki M., Tanaka Y., Kaneuchi M., Sakuragi N., Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res. 2003, 63:3913-3918.
137. Savolainen J., Forsberg M., Taipale H., Männist P.T., Järvinen K., Gynther J., Järvinen T. Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone. Drug Dev. Res. 2000, 49:238-244.
138. Savolainen J., Leppänen J., Forsberg M., Taipale H., Nevalainen T., Huuskonen J., Gynther J., Männist P.T., Järvinen T. Synthesis and in vitro and in vivo evaluation of novel orally administered N-alkyl- and N,N-dialkyl-carbamate esters of entacapone. Life Sci. 2000, 67:205-216.
139. Schultz E., Nissinen E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem. Pharmacol. 1989, 38:3953-3956.
140. Seeman P., Weinshenker D., Quirion R., Srivastava L., Bhardwaj S.K., Grandy D.K., Premont R., Sotnikova T., Boksa P., El-Ghundi M., O'Dowd B.F., George S.R., Perrault M.L., Männist P.T., Robinson S., Palmiter R.D., Tallerico T. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:3513-3518.
141. Sharpless N.S., Tyce G.M., Owen C.A. Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues. Life Sci. 1973, 12:97-106.
142. Shintani F., Kinoshita T., Kanba S., Ishikawa T., Suzuki E., Sasakawa N., Kato R., Asai M., Nakaki T. Bioactive 6-nitronorepinephrine identified in mammalian brain. J. Biol. Chem. 1996, 271:13561-13565.
143. Slomiany B.L., Liau Y.H., Lopez R.A., Slomiany A. Nitecapone effect on the synthesis and secretion of gastric sulfomucin. Gen. Pharmacol. 1993, 24:69-73.
144. Smith L.A., Gordin A., Jenner P., Marsden C.D. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov. Disord. 1997, 12:935-945.
145. Steulet A.-F., Stöcklin K., Wicki P., Waldmeier P. Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis. Neurochem. Res. 1993, 18:1131-1136.
146. Suzuki Y.J., Tsuchiya M., Safadi A., Kagan V.E., Packer L. Antioxidant properties of nitecapone (OR-462). Free Radical Biol. Med. 1992, 13:517-525.
147. Suzuki G., Harper K., Hiramoto T., Kang G., Buell M., Geyer M., Weinberger D., Funke B., Kucherlapati R., Morrow B., Männist P., Agatsuma S., Hiroi N. Over-expression of a human 22q11.2 segment, including TXNRD2, COMT and ARVCF, developmentally affects motivation and working memory in mice. Hum. Mol. Gen. 2009, 18:3914-3925.
148. Tai C.H., Wu R.M. Catechol-O-methyltransferase and Parkinson's disease. Acta Med. Okayama. 2002, 56:1-6.
149. Takehiro, I., Hitoshi, I., Satoko, K., Masako, Y., Hiroaki, S., Yasunori, U., and Nobuyuki, T. (2009). Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition. WIPO Patent Appl. WO/2009/081,891 A1.
150. Tammimäki A., Forsberg M., Gogos J., Karayiorgou M., Männist P.T. Increase in free choice oral ethanol self-administration in with catechol-O-methyltransferase gene-disrupted male mice. Basic Clin. Pharmacol. Toxicol. 2008, 103:297-304.
151. Tammimäki A., Kulessjaya N., Keisala T., Rauvala H., Käenmäki M., Kambur O., Männist P. Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. Psychopharmacology. (Berl). 2010, 211:389-401.
152. Tarpila S., Karvonen A.L., Lehtola J., Kultalahti E.R., Akkila J. Cytoprotective effect of nitecapone on gastric irritation caused by aspirin in man. Gastroenterology 1990, 98:A136.
153. Taskinen J., Vidgren J., Ovaska M., Bäckström R., Pippuri A., Nissinen E. QSAR and binding model for inhibition of rat liver catechol-O-methyltransferase by 1,5-substituted-3,4-dihydroxybenzenes. Quant. Struct.-Act.Relat. 1989, 8:210-213.
154. Tchivileva I.E., Nackley A.G., Qian L., Wentworth S., Conrad M., Diatchenko L.B. Characterization of NF-kB-mediated inhibition of catechol-O-methyltransferase. Mol. Pain. 2009, 5:13.
155. Tenorio-Laranga J., Männist P.T., Gogos J., Karayiorgou M., Garcia-Horsman A. Sex-dependent compensated oxidative stress in the mouse liver upon deletion of catechol-O-methyltransferase. Biochem. Pharmacol. 2009, 77:1541-1552.
156. Tiainen, E., Bäckström, R., Ahlmark, M., Pystynen, J., and Luiro, A. (2009). New Pharmaceutical compounds. US 2009/0209532 A1.
157. Törnwall M., Kaakkola S., Tuomainen P., Kask A., Männist P.T. Comparison of two new inhibitors of catechol O-methyltransferase on striatal dopamine metabolism: a microdialysis study in rats. Br. J. Pharmacol. 1994, 112:13-18.
158. Törnwall M., Männist P.T. Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. Eur. J. Pharmacol. 1993, 250:77-84.
159. Tuomainen P., Törnwall M., Männist P.T. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats. Pharmacol. Toxicol. 1996, 78:392-396.
160. Vento A.E., Räm O.J., Nemlander A.T., Nissinen E., Holopainen A., Mattila S.P. Nitecapone is of benefit to functional performance in experimental heart transplantation. Res. Exp. Med. 1997, 197:137-146.
161. Vidgren J., Ovaska M. Structural aspects in the inhibitor design of catechol O-methyltransferase. Structure-Based Drug Design 1997, 343-363. Marcel Dekker, Inc, New York. P. Veerapandian (Ed.).
162. Vieira-Coelho M.A., Soares-da-Silva P. Alpha(2)-adrenoceptors mediate the effect of dopamine on adult rat jejunal electrolyte transport. Eur. J. Pharmacol. 1998, 356:59-65.
163. Vidgren J., Svensson L.A., Liljas A. Crystal structure of catechol O-methyltransferase. Nature 1994, 368:354-358.
164. Vieira-Coelho M.A., Soares-da-Silva P. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br. J. Pharmacol. 1996, 117:516-520.
165. Waldmeier P.C., Baumann P.A., Feldtrauer J.J., Hauser K., Bittiger H., Bischoff S., Von Sprecher G. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch. Pharmacol. 1990, 342:305-311.
166. Waldmeier P.C., De Herdt P., Maitre L. Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-DOPA in the rat. J. Neural. Transm. Suppl. 1990, 32:381-386.
167. Waldmeier P.C., Buchle A.M., Steulet A.F. Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylases by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem. Pharmacol. 1993, 45:2417-2424.
168. Waters C.H., Kurth M., Bailey P., Shulman L.M., LeWitt P., Dorflinger E., Deptula D., Pedder S. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology 1997, 49:665-671.
169. Weisz J., FritzWolz G., Clawson G.A., Benedict C.M., Abendroth C., Creveling C.R. Induction of nuclear catechol-O-methyltransferase by estrogens in hamster kidney: implications for estrogen-induced renal cancer. Carcinogenesis. 1998, 19:1307-1312.
170. Woodard R.W., Tsai M.-D., Floss H.G., Crooks P.A., Coward J.K. Stereochemical course of the transmethylation catalyzed by catechol-O-methyltransferase. J. Biol. Chem. 1980, 255:9124-9127.
171. Xie T., Ho S.L., Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol. Pharmacol. 1999, 56:31-38.
172. Yavich L., Forsberg M., Gogos J., Karayiorgou M., Männist P.T. Site specific role of COMT in dopamine overflow within prefrontal cortex and dorsal striatum. J. Neurosci. 2007, 27:10196-10202.
173. Zürcher G., Colzi A., Da Prada M. Ro 40-7592-inhibition of COMT in rat brain and extracerebral tissues. J. Neural. Transm. Suppl. 1990, 32:375-380.
174. Zürcher G., Dingemanse J., Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. New Developments in Therapy of Parkinson's Disease 1991, 37-43. John Libbey CIC s.r.l, Rome. A. Agnoli, G. Campanella (Eds.).
175. Zürcher G., Dingemanse J., Da Prada M. Potent COMT inhibition by Ro-40-7592 in the periphery and in the brain: preclinical and clinical findings. Adv. Neurol. 1993, 60:641-647.
176. Zürcher G., Keller H.H., Kettler R., Borgulya J., Bonetti E.P., Eigenmann R., Da Prada M. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: A pharmacological study in rats. Adv. Neurol. 1990, 53:497-503.